CATX
New Street Cheerleader
William Blair just stepped onto the sidelines and started yelling encouragement at Perspective Therapeutics. The firm initiated coverage on CATX with an Outperform rating and a $11.45 price target, basically saying the stock could have a lot more runway than its tiny share price suggests.
Why the bull case exists
The pitch is simple: radiopharmaceuticals are becoming a real thing, not just biotech conference buzzword soup. William Blair says Perspective is well positioned because of:
- its lead-212-based platform
- a peptide system designed for better tolerability
- an established supply chain, which matters a lot when you’re dealing with radioactive stuff and not just app downloads
The analyst also pointed to the broader sector setup: more reliable isotope production, growing physician experience, and a more established regulatory playbook. Translation: the science is still high-risk, but the plumbing is getting less chaotic.
The bigger beta play
What makes this interesting is that this isn’t just a one-stock victory lap. The report argues radiopharmaceuticals could address a $35 billion U.S. oncology market, which is the kind of number that makes big pharma lean in and smaller biotechs suddenly look like optionality machines.
And yes, the article name-drops the usual giants — Lilly, Bristol Myers Squibb, and AstraZeneca — as examples of how serious money has already been hunting in this space. That doesn’t make them the point of the story, but it does show the industry is getting crowded in a hurry.
Big picture
Perspective shares were still down a bit on the day the piece ran, so the market wasn’t exactly throwing confetti. But analyst coverage like this can matter for a name this small: when Wall Street starts assigning a much higher fair value, the stock can go from “niche biotech” to “wait, maybe this thing has a real market.”